Maple syrup urine disease

Codexis Reports First Quarter 2024 Financial Results

Retrieved on: 
목요일, 5월 2, 2024
Maple syrup urine disease, Element, Investment, SAB, RNA interference, MBBS, Alnylam Pharmaceuticals, MSUD, Ligation, Research and development, Control, Doctor of Philosophy, HCU, Administration, Roche, DNA, Senior, ECO, Marketing, MBA, Former, Advertising, GMP, Telephone, Biotechnology, McGill University, Fine chemical

REDWOOD CITY, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced financial results for the first quarter ended March 31, 2024, and provided a business update.

Key Points: 
  • Q1 Total Revenue Up 32% Year-over-year, Including Product Revenue Up 14%; Company Reiterates 2024 Financial Guidance
    REDWOOD CITY, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced financial results for the first quarter ended March 31, 2024, and provided a business update.
  • Total revenues increased by 32% to $17.1 million for first quarter 2024 compared to $13.0 million in first quarter 2023.
  • Product revenues increased by 14% to $9.6 million for first quarter 2024 compared to $8.4 million in first quarter 2023.
  • Product gross margin was 49% for first quarter 2024 compared to 46% in first quarter 2023.

Acer Therapeutics Reacquires Worldwide Development, Commercialization and Economic Rights to OLPRUVA™ from Relief Therapeutics, Excluding the Geographical Europe

Retrieved on: 
수요일, 8월 30, 2023
Heart, Principality, Maple syrup urine disease, Fatigue, BSA, Diet, Relief Therapeutics, CLA, Edema, UCD, Probenecid, Appetite, Valproate, Vomiting, Patient Information Advisory Group, Relief, UCD School of Medicine, Acquisition, Metabolism, Patient, Ammonia, Swelling, CPS, Blood, Child, Hypokalemia, European, ELA, OTC, Somnolence, ACER, Nausea, Confusion, Liver, FDA, Therapy, Lightheadedness, Headache, Potassium, Sodium, Neurotoxicity, Haloperidol, Pharmaceutical industry, Maple syrup, Acer

OLPRUVA™ is approved in the U.S. for the treatment of certain urea cycle disorders (UCDs).

Key Points: 
  • OLPRUVA™ is approved in the U.S. for the treatment of certain urea cycle disorders (UCDs).
  • Acer and Relief have now agreed to terminate the CLA, where Acer is no longer required to pay Relief 60% of OLPRUVA™ net profits in the Acer territories and have regained all development and commercialization rights in rest of the world, excluding the Geographical Europe.
  • Additionally, Acer and Relief have entered into a new Exclusive License Agreement (ELA) in which Relief will retain development and commercialization rights for OLPRUVA™ in the Geographical Europe, where Acer will have the right to receive a royalty of up to 10% of the net sales of OLPRUVA™.
  • For additional Important Safety Information, see full Prescribing Information , Patient Package Insert and discuss with your doctor.

Acer Therapeutics Reports Q4 and Full Year 2022 Financial Results and Provides Corporate Update

Retrieved on: 
월요일, 3월 27, 2023
Society, Epilepsy, Food and Drug Administration, Prescription, MSUD, Acquisition, Patent, Patient, Menopause, Collaboration, Celiprolol, Diet, VMS, Contra, Syndrome, UCD, PCDC, Sodium benzoate, Ammonia, CPS, FDA, Body surface area, Maple syrup urine disease, BSA, Liver, SIMD, Hot, Maharishi Sandipani Rashtriya Ved Vidya Pratishthan, Annual report, Blood, ACER, Research, Therapy, Medicaid, Information technology, Clinical trial, United States patent law, Woman, Urea, Sale, State Administrative Expenses, UCD School of Medicine, OTC, Annual general meeting, Food, Pharmaceutical industry, Cryptocurrency, Maple syrup, Acer, Discover

OLPRUVA™ is not used to treat rapid increase of ammonia in the blood (acute hyperammonemia), which can be life-threatening and requires emergency medical treatment.

Key Points: 
  • OLPRUVA™ is not used to treat rapid increase of ammonia in the blood (acute hyperammonemia), which can be life-threatening and requires emergency medical treatment.
  • As a result, Acer is pausing the ACER-801 program until Acer has conducted a thorough review of the full data set
    Ended Q4 2022 with $2.3 million in cash and cash equivalents.
  • Cash and cash equivalents were $2.3 million as of December 31, 2022, compared to $12.7 million as of December 31, 2021.
  • For additional information, please see Acer’s Annual Report on Form 10-K filed today with the SEC.

Acer Therapeutics Highlights Key 2022 Achievements and Pipeline Advancements, and Provides Anticipated 2023 Milestones

Retrieved on: 
월요일, 1월 9, 2023
MA, Liver, Flash, Caregiver, Trauma, Aircraft pilot, Partnership, Intellectual property, Woman, IVMS, Acquisition, Adenocarcinoma, UCD School of Medicine, Prostate, University, UCD, Ammonia, Epilepsy, Food, Maple syrup urine disease, BSA, ACER, Blood, Education, Therapy, MSUD, Body surface area, Severity, FDA, VED, Post-traumatic stress disorder, VMS, Mouse, United States Department of Defense, Prostate cancer, OTC, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Celiprolol, PCDC, PTSD, Patient, Diet, Emory University, Testosterone, Disorder, CPS, Pharmaceutical industry, Discover, Acer, Osanetant

NEWTON, MA – January 09, 2023 – Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious, rare and life-threatening diseases with significant unmet medical needs, today announced a corporate update and provided anticipated key development milestones for 2023.

Key Points: 
  • NEWTON, MA – January 09, 2023 – Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious, rare and life-threatening diseases with significant unmet medical needs, today announced a corporate update and provided anticipated key development milestones for 2023.
  • “Our commitment to patients is the cornerstone of our mission, and we are proud to have secured our first FDA approval.
  • We are eager to report the topline results from our ongoing Phase 2a trial of ACER-801 in moderate to severe VMS in post-menopausal women in Q1 of 2023.
  • These trial results will provide important insight into ACER-801’s therapeutic potential in induced VMS (iVMS).

Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. Announce Close of Definitive Settlement Agreements

Retrieved on: 
화요일, 12월 20, 2022
Dark Enlightenment, Maple syrup urine disease, SA, Security (finance), Neurological disorder, UCD School of Medicine, Patient, Liu v. Securities and Exchange Commission, Food, SIX Swiss Exchange, Suicide, Depression, Patent, COVID-19, RLF, FDA, MSUD, PTSD, Phenylketonuria, LR, PKU, Ketamine, Breakthrough, FDA Special Protocol Assessment, Epidermolysis bullosa, EB, Food and Drug Administration Safety and Innovation Act, OTCQB, Therapy, Metabolism, Post-traumatic stress disorder, Database, Connective tissue, Acer, Aviptadil, Pulmonology, Hypochlorous acid, NMDA, Pharmaceutical industry, Relief

GENEVA and RADNOR, Pa., Dec. 20, 2022 /PRNewswire/ -- RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) ("Relief"), and NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals"), a clinical-stage central nervous system biopharmaceutical company, today announced the close of the definitive settlement agreements to resolve the pending litigation between Relief and NRx Pharmaceuticals' wholly owned subsidiary, NeuroRx, Inc (NeuroRx). Per the terms of the settlement, (i) NeuroRx has transferred to Relief all of the assets it used in the NRx aviptadil development program, including the regulatory filings, patent applications, clinical data, and the formulation of the aviptadil product it was previously developing, (ii) Relief now has the exclusive right and control going forward and the obligation to use commercially reasonable efforts to develop and commercialize an aviptadil product, (iii) Relief has agreed to use commercially reasonable efforts to continue the existing Right to Try Program for aviptadil in the U.S. for at least two years, (iv) Relief will pay NeuroRx milestone payments if it can successfully obtain commercial approval of an aviptadil product (whether for COVID-19 or any other indication), (v) Relief will pay NeuroRx royalties based on a percentage of future sales of an aviptadil product (whether for COVID-19 or any other indication), up to a maximum of $30 million in the aggregate, (vi) NRx and NeuroRx have agreed not to compete in the development of an aviptadil product in the future, and (vii) Relief and NeuroRx have dismissed their pending litigation.

Key Points: 
  • 53 LR
    GENEVA and RADNOR, Pa., Dec. 20, 2022 /PRNewswire/ -- RELIEF THERAPEUTICS Holding SA (SIX: RLF , OTCQB: RLFTF , RLFTY ) ("Relief"), and NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals"), a clinical-stage central nervous system biopharmaceutical company, today announced the close of the definitive settlement agreements to resolve the pending litigation between Relief and NRx Pharmaceuticals' wholly owned subsidiary, NeuroRx, Inc (NeuroRx).
  • Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc.
  • RELIEF THERAPEUTICS Holding SA is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbols RLFTF and RLFTY.
  • Relief and NRx do not undertake any obligation to update the information contained herein, which speaks only as of this date.

Relief Therapeutics to Participate in January Investor Meetings

Retrieved on: 
일요일, 12월 18, 2022
Epidermolysis bullosa, Maple syrup urine disease, Pulmonology, PKU, FDA, Urea, SIX Swiss Exchange, Phenylketonuria, Hypochlorous acid, Acer, OTCQB, RLF, Orphan, Patent, Therapy, Connective tissue, Metabolism, Pharmaceutical industry, Relief

Jack Weinstein, chief executive officer, will host 1 x 1 institutional investor meetings.

Key Points: 
  • Jack Weinstein, chief executive officer, will host 1 x 1 institutional investor meetings.
  • Jack Weinstein, chief executive officer, will provide an overview of Relief, its rare disease portfolio and efficient commercial footprint.
  • Mr. Weinstein will also host 1 x 1 institutional investor meetings.
  • RELIEF THERAPEUTICS Holding SA is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbols RLFTF and RLFTD.

Acer Therapeutics Announces $1.5M Private Placement

Retrieved on: 
수요일, 11월 30, 2022
COVID-19, Vipul Ved Prakash, MSUD, Fever Dream, III, Emetine, Acquisition, ACER, Therapy, Patient, Annual report, Security (finance), Maple syrup urine disease, Cytomegalovirus, Sale, Virus, COL3A1, Post-traumatic stress disorder, PTSD, Microdeletion syndrome, IVMS, Celiprolol, RCSI & UCD Malaysia Campus, Safety, Metabolism, Pharmaceutical industry, Bank, Acer

The investors are Chris Schelling, CEO and Founder of Acer, and Steve Aselage, Chairman of Acers Board of Directors.

Key Points: 
  • The investors are Chris Schelling, CEO and Founder of Acer, and Steve Aselage, Chairman of Acers Board of Directors.
  • The private placement is scheduled to close on or about December 2, 2022, subject to the satisfaction or waiver of customary closing conditions.
  • The proceeds from the private placement will be used by Acer for working capital and general corporate purposes and, together with Acers existing cash and cash equivalents, are expected to be sufficient to fund the Companys anticipated operating and capital requirements through the fourth quarter of 2022.
  • Acer is a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs.

APR Applied Pharma Research (a Subsidiary of Relief Therapeutics) is a Finalist in the 2022 Rare Disease International Film Festival

Retrieved on: 
일요일, 11월 27, 2022
Phenylketonuria, Hypochlorous acid, Food, SIX Swiss Exchange, Life, Therapy, Metabolism, Patient, Urea, Pulmonology, Epidermolysis bullosa, PKU, Acer, Diet, Disease, Orphan, Patent, Child, Maple syrup urine disease, Pathology, Connective tissue, Absorption, OTCQB, RLF, Organic acid, APR, Entertainment, Pharmaceutical industry

Geneva, Switzerland, November 21, 2022 RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTD) (Relief), a Swiss, commercial-stage biopharmaceutical company identifying, developing and commercializing novel, patent protected products in selected specialty, rare and ultra-rare disease areas on a global basis, today announced that its wholly owned subsidiary APR Applied Pharma Research SA (APR) has been nominated as a finalist in the 2022 Rare Disease International Film Festival UnoSguardoRaro .

Key Points: 
  • Geneva, Switzerland, November 21, 2022 RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTD) (Relief), a Swiss, commercial-stage biopharmaceutical company identifying, developing and commercializing novel, patent protected products in selected specialty, rare and ultra-rare disease areas on a global basis, today announced that its wholly owned subsidiary APR Applied Pharma Research SA (APR) has been nominated as a finalist in the 2022 Rare Disease International Film Festival UnoSguardoRaro .
  • APR supports and contributes to the first and only European film festival showcasing films from around the world that address the challenges of life with a rare disease.
  • As part of its participation in the festival, APR attended events in Berlin (Il Kino), Rome (la Casa del Cinema) and Milan (Niguarda hospital).
  • The festival earned the support of many rare disease associations such as:
    PKU GOLIKE is a phenylalanine-free food intended for the dietary management of phenylketonuria (PKU).

APR Applied Pharma Research (a Subsidiary of Relief Therapeutics) is a Finalist in the 2022 Rare Disease International Film Festival

Retrieved on: 
월요일, 11월 21, 2022
SIX Swiss Exchange, Urea, Metabolism, OTCQB, PKU, Epidermolysis bullosa, Connective tissue, Pathology, Absorption, Maple syrup urine disease, Diet, RLF, Therapy, MSUD, Pulmonology, Patent, Organic acid, Patient, EB, Phenylketonuria, Life, Child, Hypochlorous acid, Acer, Disease, Food, Relief, APR, Entertainment, Pharmaceutical industry

GENEVA, Nov. 21, 2022 /PRNewswire/ -- RELIEF THERAPEUTICS Holding SA (SIX: RLF) (OTCQB: RLFTF) (RLFTD) ("Relief"), a Swiss, commercial-stage biopharmaceutical company identifying, developing and commercializing novel, patent protected products in selected specialty, rare and ultra-rare disease areas on a global basis, today announced that its wholly owned subsidiary APR Applied Pharma Research SA ("APR") has been nominated as a finalist in the 2022 Rare Disease International Film Festival UnoSguardoRaro.

Key Points: 
  • GENEVA, Nov. 21, 2022 /PRNewswire/ -- RELIEF THERAPEUTICS Holding SA (SIX: RLF) (OTCQB: RLFTF) (RLFTD) ("Relief"), a Swiss, commercial-stage biopharmaceutical company identifying, developing and commercializing novel, patent protected products in selected specialty, rare and ultra-rare disease areas on a global basis, today announced that its wholly owned subsidiary APR Applied Pharma Research SA ("APR") has been nominated as a finalist in the 2022 Rare Disease International Film Festival UnoSguardoRaro.
  • APR supports and contributes to the first and only European film festival showcasing films from around the world that address the challenges of life with a rare disease.
  • During the awards ceremony, the jury awarded APR's movie 2 prizes: Special Mention for Best Campaign and Best Direction.
  • The festival earned the support of many rare disease associations such as:
    PKU GOLIKE is a phenylalanine-free food intended for the dietary management of phenylketonuria ("PKU").

Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. Announce Execution of Definitive Settlement Agreements

Retrieved on: 
월요일, 11월 14, 2022
Depression, Metabolism, Medication, Connective tissue, Food and Drug Administration Safety and Innovation Act, Acer, Program, Dark Enlightenment, Maple syrup urine disease, Urea, Therapy, Securities Exchange Act of 1934, Ketamine, MSUD, PTSD, Patent, FDA Special Protocol Assessment, Forward-looking statement, Neurological disorder, U.S. Securities and Exchange Commission, Aviptadil, Epidermolysis bullosa, SEC, Security (finance), Hypochlorous acid, SIX Swiss Exchange, FDA, NMDA, Database, RLF, EB, NASDAQ, Food, Suicide, Company, COVID-19, OTCQB, Post-traumatic stress disorder, Patient, SA, Breakthrough, PKU, Pulmonology, Phenylketonuria, LR, Pharmaceutical industry, Relief

GENEVA and RADNOR, Pa., Nov. 14, 2022 /PRNewswire/ -- RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTD) ("Relief"), and NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) ("NRx Pharmaceuticals"), today announced that they have entered into definitive settlement agreements to resolve their pending litigation.  As part of the settlement, at a closing to be held within the next 30 days, (i) NRx Pharmaceuticals will transfer to Relief all of the assets that it previously used in its aviptadil development program, including its regulatory filings, patent applications, clinical data, and the formulation of the aviptadil product it was previously developing, (ii) Relief will have the exclusive right and control going forward and the obligation to use commercially reasonable efforts to develop and commercialize an aviptadil product, (iii) Relief has agreed to use commercially reasonable efforts to continue the existing Right to Try Program for aviptadil in the United States for at least 2 years, (iv) Relief will pay NRx Pharmaceuticals milestone payments if it can successfully obtain commercial approval of an aviptadil product (whether for COVID-19 or any other indication), (v) Relief will pay NRx Pharmaceuticals royalties based on a percentage of future sales of an aviptadil product (whether for COVID-19 or any other indication), up to a maximum of $30 million in the aggregate, (vi) NRx Pharmaceuticals has agreed not to compete in the development of an aviptadil product in the future, and (vii) at the closing, Relief and NRx Pharmaceuticals will dismiss their pending litigation. There can be no assurances that Relief will be successful at commercializing the aviptadil product.

Key Points: 
  • 53 LR
    GENEVA and RADNOR, Pa., Nov. 14, 2022 /PRNewswire/ -- RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTD) ("Relief"), and NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) ("NRx Pharmaceuticals"), today announced that they have entered into definitive settlement agreements to resolve their pending litigation.
  • There can be no assurances that Relief will be successful at commercializing the aviptadil product.
  • Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc.
  • Relief and NRx do not undertake any obligation to update the information contained herein, which speaks only as of this date.